CACNA1S Genotype

One inherited change in this gene can turn a routine operation into a crisis. Under volatile anesthetic gases or succinylcholine, calcium can flood out of control inside muscle, temperature climbs, and the outcome depends on how fast the team recognizes what is happening. Know the genotype in advance and the anesthesiologist can pick different drugs, so the crisis never starts.

The same gene can explain two other things people rarely connect: attacks of severe weakness that arrive with low blood potassium, and lifelong muscle pain with enzyme levels that stay high for no clear reason. The result never changes, so you test once. What you do with it lasts decades.

The Switch That Starts Every Muscle Contraction

CACNA1S carries the instructions for a protein called CaV1.1, spread across 44 coding exons. Older papers call the same protein the dihydropyridine receptor. It is specific to skeletal muscle, the muscle you move on purpose, where it sits in the membrane folds that carry electrical signals into the fiber.

Its job is to start contraction. A nerve signal arrives, the muscle membrane changes charge, and CaV1.1 feels that change and physically pushes on a neighboring protein called RyR1. RyR1 opens a gate and releases stored calcium into the cell, which is what makes the fiber shorten.

Rebuilding this system in experimental cells takes only four proteins: CaV1.1 itself, two partner proteins that hold it in place and pass the signal along, and RyR1. That is a short chain with no backup, which is why a single amino acid swap in the wrong spot can have effects this large.

Malignant Hyperthermia Susceptibility

This is why the gene made the American College of Medical Genetics and Genomics list of genes worth telling someone about even when the finding turns up by accident in a broader test. Malignant hyperthermia is a runaway reaction to volatile anesthetic gases and to succinylcholine, a muscle relaxant sometimes used when placing a breathing tube. It is inherited in a dominant pattern, so one copy is enough. The reason knowing matters is that the trigger drugs are avoidable and safe alternatives exist.

Most malignant hyperthermia is not this gene. In a UK study of 795 malignant hyperthermia-susceptible families, 555 carried a potentially causative variant, and almost all the recurrent ones sat in a different gene, RYR1. RYR1 produced 25 statistically over-represented recurrent variants; this gene produced one. Labs sequence both together for exactly that reason. A third gene, STAC3, which codes for one of the partner proteins in that four-protein chain, accounts for a small number of susceptible families, mostly alongside a congenital muscle disease first described in Native American communities.

Sequencing does find what older methods missed. In four families where Sanger sequencing had come up empty, exome sequencing found rare candidate variants: three in RYR1 and one in CACNA1S, Thr1009Lys. That CACNA1S signal was promising but not clean; later work found people with the same variant who tested negative on the diagnostic muscle test, so results like this need family data and lab testing before they become actionable. A resequencing array applied to 121 people already known to be susceptible found new variants in 21 who had previously tested negative. Targeted sequencing of both genes in 29 people with confirmed malignant hyperthermia and 28 who had collapsed from overheating during hard exercise found one uncertain CACNA1S variant in the first group and three in the second.

If a lab calls your variant pathogenic, the practical consequence is small and permanent: a note in your chart, a line on every pre-operative form, and an anesthetic plan built around drugs that do not trigger the reaction. That is the whole payoff. You avoid the exposure instead of surviving it.

Hypokalemic Periodic Paralysis

The second syndrome is easy to miss because it comes and goes. Weakness builds over hours, blood potassium runs low during the attack, and strength returns in between. The mutations behind it cluster in the voltage-sensing segments of the channel. Most cases come from losing one charged amino acid in those segments, and two CACNA1S changes alone, R528H and R1239H, account for about 70% to 80% of CACNA1S-related cases.

Which gene carries the blame depends on ancestry. In a Chinese series of 37 people with primary periodic paralysis, sequencing found an answer in 59.5% overall, with CACNA1S variants in 6 of 21 hypokalemic cases and most of the rest in SCN4A, a gene for a muscle sodium channel. In Europe and the United States, CACNA1S is the more common cause.

Carrying the variant does not mean having attacks. In one Chinese family with the R900S change, every male carrier had episodes of weakness and all three female carriers had none. A variant described more recently, R897K, produced weakness in 14 people across five families, with pelvic-girdle weakness the common thread and changes visible on muscle MRI.

Treatment aims at the attacks, not the gene. In the R900S family, triamterene with potassium supplements cut how often weakness struck, which is one family's experience rather than a trial. Periodic paralysis also occurs alongside an overactive thyroid, so thyroid function is worth checking in anyone with episodes, because that cause is treatable on its own terms.

Congenital Myopathy and Weakness From Birth

Both recessive and dominant changes in this gene cause a muscle disease that shows up at or before birth. In 11 patients from 7 families, the picture was low muscle tone in the newborn period and severe weakness through the trunk and limbs. Four patients also had limited eye movement. Four of those families carried two different damaged copies, one from each parent, and lab work on their muscle cells showed less channel protein and weaker calcium release.

The severe end reaches back into pregnancy. Sequencing in 190 probands affected by fetal akinesia or arthrogryposis found two inherited CACNA1S changes, p.Met222Lys and p.Arg789Cys, in one family with recurrent fetal akinesia. A neuromuscular panel applied to 28 newborns on ventilators for floppiness gave an answer in 43% of them, including one pathogenic CACNA1S variant.

For an adult reading this, that end of the spectrum matters mostly for reproductive planning. For the recessive forms, one carrier copy by itself may not cause the severe newborn disease. Two inherited together is a different conversation, and a genetic counselor is the right person for it.

Muscle Pain, Cramping, and Enzymes That Stay High

There is a milder picture between those extremes, and it only got named recently. Creatine kinase is the enzyme that leaks out of damaged muscle into the blood. Variants here have been tied to exercise-induced muscle pain, cramping, stiffness, fatigue, and enzyme levels that drift high and stay there without an obvious cause.

In a Finnish family, a rare change called p.E965Q produced exercise pain, cramping, and slowly progressive weakness across six relatives. Another variant, p.Arg1242Gly, came with episodes of muscle breakdown after exertion and fluctuating high enzymes even when the person felt fine. A 2025 review described 15 people with this pattern, spanning the ground between periodic paralysis and congenital myopathy, and some ended up using a wheelchair or walking aid.

If you have had one unexplained episode of muscle breakdown after training hard, or your muscle enzymes keep coming back high and nobody can say why, this is the part of the gene's story worth reading twice. It is also the part most likely to be missed, because the symptoms sound like ordinary overtraining.

Why Finding a Variant Is Not the Same as Finding a Risk

Two facts about this gene are both true and pull in opposite directions. It is on the short list of genes worth reporting when found incidentally. And a whole-genome study of 62,240 Icelanders found 125 rare coding or splice-site variants in it and classified none of them as actionable against the public database labs use to log these calls.

The gene is unusually variable. It ranks among the more genetically diverse genes in the human genome, and in one large American exome database nearly everyone carried at least one variant that prediction software flagged as possibly damaging. Variants here are ordinary. Disease-causing variants are not.

So read this as a specific-variant test rather than a good-result-versus-bad-result test. The value sits in a short list of changes pinned down two ways: by tracking through affected families, and by lab work showing the channel actually misbehaves. In 870 unselected exomes, 53 CACNA1S variants turned up, and several that databases had called pathogenic were downgraded to uncertain once they appeared in people with no symptoms at all.

Newer associations sit further out still. A forensic study of 98 sudden unexplained nocturnal deaths in Thailand found CACNA1S, RYR1, or combined missense variants in 16.3% of the cases, which raises a question about this machinery and sudden death without answering it. Nothing in that finding changes what you should do today.

When a Result Can Mislead You

• A negative result does not clear you for anesthesia: an estimated 14% to 23% of malignant hyperthermia families carry susceptibility outside RYR1 and CACNA1S, the two genes labs routinely sequence, so a clean sequence lowers the odds without settling them.
• Coverage has limits: sequencing reads the coding regions of all 44 exons at high depth, which is better than older methods, but changes buried deep in the non-coding parts of the gene and large structural deletions can still slip past.
• Expect uncertain calls: two novel variants in the Chinese periodic paralysis series, V470M and R1302Q, were left as uncertain pending family tracking and functional testing. An uncertain result is a common outcome here, not a lab error.
• Ancestry changes the meaning: this gene is the dominant cause of hypokalemic periodic paralysis in Europe and the United States and a minority cause in the Chinese cohort, and the frequency databases used to filter variants still skew heavily European.
• The source has to be clinical inherited DNA: blood, saliva, and buccal cells should give the same germline call, but a tumor-only sequence, a poor swab, or raw consumer data is not the same as a clinical inherited-variant report.

You Test Once, Then Use It for Years

Your sequence does not change, so there is nothing to retest. The only reason to run it again is doubt about the call itself. When a result is unexpected or will change anesthesia plans, confirmation by a second method can settle whether the call is real. Keep the full report, not just the summary line, because classifications get revised as more families are studied and you will want the exact variant name when that happens.

What does need repeating is downstream testing, not the gene. If you carry a variant tied to muscle pain and high enzyme levels, get a baseline creatine kinase and repeat it if symptoms change, especially after dark urine or severe soreness following exercise. If you get attacks of weakness, potassium has to be drawn during an attack to be worth anything; a normal value between episodes tells you nothing.

What to Do With an Unexpected Result

A pathogenic variant linked to anesthesia risk is an administrative task more than a medical one. Get it into your chart, onto your surgical paperwork, and onto whatever you carry in an emergency, then ask for an anesthesia consultation before any elective procedure rather than on the morning of it. Then tell your biological relatives, because each first-degree relative has a one in two chance of carrying the same copy.

If the result pairs with symptoms, the next step is a neuromuscular neurologist rather than another gene test. Bring the pattern, not just the variant: episodes of weakness with documented low potassium point one direction, persistent high muscle enzymes with exercise pain point another, and muscle MRI and occasionally a biopsy are what separate them. Thyroid testing belongs in that workup for anyone with episodic weakness.

An uncertain variant is where judgment matters. The move that resolves it is testing affected and unaffected relatives to see whether the variant travels with the symptoms, which a genetic counselor can organize. Until then, raise it with your anesthesiologist anyway, because choosing a non-triggering anesthetic costs almost nothing while waiting for certainty could cost a great deal.

The combination that should push you hardest is a variant plus a family story: a relative who spiked a fever and went rigid in the recovery room, an anesthetic death nobody ever explained, or a parent with attacks of weakness that got written off. Genotype alone is a probability. Genotype plus that history is a plan.